Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma:
- Pfizer acquired Seagen for $43 billion
- AbbVie invested over $10 billion in ImmunoGen
- Merck committed $4 billion upfront, with a potential total of $22 billion, for a stake in three of Daiichi Sankyo’s ADCs
Wondering what all the fuss is about and why would-be investors are priced out of the market?
Read our report now for insights on the market landscape, including complexities in the field and key deal drivers. Find out who’s top of the pile and who’s poised to make the next move.
